Jpmorgan Chase & CO Protalix Bio Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
A detailed history of Jpmorgan Chase & CO transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 32,518 shares of PLX stock, worth $35,119. This represents 0.0% of its overall portfolio holdings.
Number of Shares
32,518
Previous 43,734
25.65%
Holding current value
$35,119
Previous $77,000
48.05%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding PLX
# of Institutions
66Shares Held
9.27MCall Options Held
40.6KPut Options Held
10.1K-
Black Rock Inc. New York, NY3.31MShares$3.58 Million0.0% of portfolio
-
State Street Corp Boston, MA827KShares$892,7070.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny825KShares$890,6760.0% of portfolio
-
Geode Capital Management, LLC Boston, MA754KShares$814,4380.0% of portfolio
-
Gsa Capital Partners LLP London, X0494KShares$533,0560.05% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $53.7M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...